Ning Zan
Xuan Zhang
Danfei Yu
*The final, formatted version of the article will be published soon.
CASE REPORT article
Front. Oncol.
Sec. Gynecological Oncology
Volume 14 - 2024 |
doi: 10.3389/fonc.2024.1481251
This article is part of the Research Topic Management of Rare Oncological Cases View all 47 articles
Case Report: Long-term Progression-Free Survival in Advanced Ovarian Cancer Treated with Apatinib in First-line Maintenance Treatment
Provisionally accepted- The People's Hospital of Leshan, Leshan, China
Ovarian cancer is one of the most common gynecological malignancies. The current first-line treatment strategies for advanced ovarian cancer include surgery, chemotherapy, and maintenance therapy. Bevacizumab and poly (ADP-ribose) polymerase inhibitors (PARPi) are primary maintenance treatments for advanced ovarian cancer. Previously, many patients declined these therapies before medicare coverage because of high costs. Bevacizumab and apatinib are anti-tumor angiogenic agents. In this case study, we describe a patient with advanced ovarian cancer who underwent neoadjuvant chemotherapy, interval debulking surgery, and adjuvant chemotherapy. She declined bevacizumab and PARPi maintenance therapy owing to the prohibitive expenses. The patient was administered off-label apatinib and achieved a progression-free survival of 54 months. Thus, apatinib may offer substantial therapeutic value as a first-line maintenance therapy in advanced ovarian cancer.
Keywords: ovarian cancer, maintain therapy, Angiogenic, Apatinib, Gynecology, case report
Received: 15 Aug 2024; Accepted: 07 Oct 2024.
Copyright: © 2024 Zan, Zhang, Yu, Liu, Lin and Zhu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Danfei Yu, The People's Hospital of Leshan, Leshan, China
Juan Liu, The People's Hospital of Leshan, Leshan, China
Zhiyu Lin, The People's Hospital of Leshan, Leshan, China
Yanlin Zhu, The People's Hospital of Leshan, Leshan, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.